



## **Bemcentinib**

Catalog No: tcsc1046

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 1037624-75-1
Formula: $C_{30}^{H}_{34}^{N}_{8}$
Pathway: Protein Tyrosine Kinase/RTK
Target: TAM Receptor
Purity / Grade: >98%
Solubility: DMSO: 10.25 mg/mL (20.23 mM; Need ultrasonic and warming)
Alternative Names: R428;BGB324
Observed Molecular Weight: 506.64



## **Product Description**

Bemcentinib (R428) is a potent and selective inhibitor of  $\mathbf{AxI}$  with an  $\mathbf{IC}_{\mathbf{50}}$  of 14 nM.

IC50 & Target: IC50: 14 nM (Axl kinase)

In Vitro: Bemcentinib (R428) ( $2\mu$ M) significantly interferes with mechanisms of migration and invasion of Axlpos melanoma cells at levels comparable to Axl knockdown<sup>[1]</sup>. Bemcentinib (R428) synergizes with cisplatin to enhance suppression of liver micrometastasis <sup>[2]</sup>. Bemcentinib (R428) (50 nM-1 $\mu$ M) causes a concentration-dependent inhibition of preadipocyte differentiation into mature adipocytes, as evidenced by reduced lipid uptake<sup>[3]</sup>.

In Vivo: Bemcentinib (R428) (125 mg/kg, p.o.) significantly blocks MDA-MB-231-luc-D3H2LN metastases development in two independent mouse models of breast cancer dissemination, suppresses both tumor angiogenesis and vascular endothelial growth factor (VEGF)-induced corneal neovascularization in vivo<sup>[2]</sup>. Bemcentinib (R428) (75 mg/kg/day, 25 mg/kg twice daily, p.o.) makes mice keep on a high-fat diet resulted in significantly reduced weight gain and subcutaneous and gonadal fat mass<sup>[3]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!